Studies: Lenalidomide for 5q-syndrome

ID Trial

RV-MDS-PI-409

EudraCT number

2008-001866-10

Clinicaltrials.gov identifier

NCT01081431

Description

A multicenter, single-arm, open-label phase II study of the safety of lenalidomide monotherapy and markers for disease progression in patients with IPSS low or intermediate-1 myelodysplastic syndromes (MDS) associated with an isolated 5q cytogenetic abnormality (del 5q)

Status

closed

Disease

Disease Stage  
myelodysplastic syndrome 5q- syndrome

Coordinating investigator

No data

Principal investigator

Prof. Dr. A. Ganser
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
Carl-Neuberg-Str. 1
30625 Hannover
Germany

Study nurse

D. Ihlenburg-Schwarz
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
Carl-Neuberg-Str. 1
30625 Hannover
Germany
Phone: 0511 532-6394
Fax: 0511 532-9665
Email ihlenburg-schwarz.daniela@mh-hannover.de